Evaluation of different MET genotypes as biomarkers for immunotherapy outcomes in NSCLC patients.

e21032Background: Previous studies suggested that MET exon 14 (METex14) mutation regarding as a distinct subset was sensitive to MET-inhibitors, but poorly response to immunotherapy. Conversly, MET...